Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoflupredone is a synthetic corticosteroid used primarily in veterinary medicine for its potent anti-inflammatory and immunosuppressive effects. It acts as an agonist at both glucocorticoid and mineralocorticoid receptors, modulating gene transcription and protein synthesis to reduce inflammation and immune responses. Isoflupredone is commonly administered as the acetate ester (isoflupredone acetate) via injectable or topical formulations, with FDA approval for use in horses, cattle, and pigs. Indications include treatment of musculoskeletal disorders, allergic reactions, recurrent airway obstruction (heaves), ketosis in cattle, shock, hypersensitivity reactions, infections with severe toxicity, and other inflammatory diseases. The drug exhibits both disease-modifying and symptom-modifying effects but requires careful use due to risks such as delayed wound healing or hypokalemia[4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoflupredone.